Cancer Therapeutics

癌症治疗计划的三个目标是：1）加强和促进癌症治疗基础科学家和临床研究者之间的计划和跨计划互动和合作; 2）促进新治疗方法的发现，开发和应用; 3）开发新治疗药物和新治疗方法的转化和实验室临床研究。这些目标是通过三个研究主题来实现的。主题1侧重于靶点识别和药物发现的技术开发，目标是将这些新技术（如组合化学，药物化学，计算生物学，结构生物学，纳米技术和高通量分析）应用于主题2中的特定药物开发项目。例如，在主题2中，我们正在开发：癌细胞表面靶向配体，用于癌症药物递送和成像的新型靶向纳米载体，酪氨酸激酶抑制剂，以及用于癌症疫苗和免疫治疗的纳米颗粒。在主题3中，我们使用分子生物学家，转化科学家，药理学家和临床研究者的协作组来促进实验室驱动的临床研究的设计和实施。鉴于该计划在药物发现和药物开发方面的临床前专业知识，有很大的潜力将有前途的新治疗线索转化为临床试验和相关的实验室相关研究。这种转化的一个例子是即将在人体中进行测试的紫杉醇新纳米制剂的开发。此外，这组研究人员的专业知识为从NCI或行业获得新的治疗药物提供了渠道。为临床试验提供平台的是临床研究和转化研究的特定项目领域，包括药物开发奖（N 01，U 01，U10）和药物启动试验。该计划有来自加州大学戴维斯分校13个不同部门和LLNL 1个部门的46名成员。它有25个NCI资助的项目，390万美元ADC（同行评审的资金总额为880万美元ADC）。在上一个供资期的728份出版物中，44%是计划间出版物，29%是计划内出版物。

The three goals of the Cancer Therapeutic Program are: 1) to enhance and facilitate programmatic and interprogrammatic interaction and collaboration between basic scientists and clinical investigators in cancer therapeutics; 2) to promote the discovery, development, and application of novel therapeutic approaches; and 3) to develop translational and laboratory-based clinical investigations of new therapeutic agents and new therapeutic approaches. These goals are achieved through three Research Themes. Theme 1 is focused on technology development for target identification and drug discovery, with the goal of applying these new technologies (such as combinatorial chemistry, medicinal chemistry, computational biology, structural biology, nanotechnology, and high-throughput assays) to specific drug development projects in theme 2. For example, in theme 2, we are developing: cancer cell surface targeting ligands, novel targeting nanocarriers for cancer drug delivery and imaging, tyrosine kinase inhibitors, and nanoparticles for cancer vaccine and immunotherapy. In Theme 3, we use a collaborative group of molecular biologists, translational scientists, pharmacologists, and clinical investigators to facilitate the design and conduct of laboratory-driven clinical investigations. In view of the preclinical expertise in drug discovery and drug development available within the Program, there is great potential to translate promising new therapeutic leads into clinical trials and associated laboratory correlative studies. One example of such translation is the development of novel nanoformulations of paclitaxel soon to be tested in human. Furthermore, the expertise represented within this group of investigators provides a conduit for acquisition of new therapeutic agents from the NCI or industry. Providing a platform for clinical trials are specific project areas in clinical investigation and translational studies, including drug development awards (N01, U01, U10) and investigator-initiated trials. The program has 46 members from 13 different departments at UC Davis and 1 department at LLNL. It has 25 NCl-funded projects for $3.9 million ADC (total peer-reviewed funding, $8.8 million ADC). Of the 728 publications for the last funding period, 44% are inter-programmatic and 29% are intra-programmatic.